Understand · Treat · Recover

Recurrent and Metastatic Head & Neck Cancer

The first question after recurrence is whether another curative local treatment remains possible.

Patient education only. This guide does not diagnose cancer or prescribe treatment. Your team must adapt decisions to your cancer, health, preferences and local resources.

All 25 chapters

Chapter 19 of 25

Not all recurrence has the same meaning

Local recurrence is cancer returning at the original site; regional recurrence affects nearby nodes. Distant metastasis is spread to organs such as lungs, bones or liver. A new lesion can also be a second primary cancer. Imaging and, when appropriate, biopsy help distinguish these possibilities before treatment is selected.

Some localized recurrences remain potentially curable with salvage surgery or carefully selected re-irradiation. Oligometastatic disease means a limited number of distant deposits; local treatment can be considered for selected people, but the word alone does not guarantee cure. Widely metastatic disease is generally treated with goals of control, symptom relief and maintaining quality of life.

Local treatments and their trade-offs

Salvage surgery must consider whether complete removal is achievable and what function will remain. Re-irradiation needs expert review of the previous dose, time since treatment, critical structures and present health. It can cause serious late injury, including tissue damage and bleeding, and is not suitable for everyone.

Palliative radiation can relieve a painful or bleeding tumour even when other sites of cancer remain. Airway management, feeding support and treatment of infection may need to happen before systemic therapy. Supportive care is a central treatment component rather than something reserved until anticancer options run out.

Choosing first-line systemic treatment

The oncologist considers PD-L1 CPS, prior platinum, the interval since previous treatment, disease speed, symptoms, kidney function, fitness and patient goals. Pembrolizumab alone is an option for eligible PD-L1-positive recurrent or metastatic squamous cancer, particularly when the clinical situation allows time for an immune response. It has a lower chance of early tumour shrinkage than some combinations and is not ideal simply because it avoids chemotherapy.

Pembrolizumab with platinum and 5-FU is an established combination; other chemotherapy partners may be selected according to evidence, tolerability and local guidance. Cetuximab-based regimens, including platinum combinations, or taxane-based treatment remain options when appropriate. A high CPS does not remove the need to consider urgent symptom relief, and a low CPS requires careful interpretation of the relevant indication.

After platinum or immunotherapy

Nivolumab has evidence in platinum-refractory disease from CheckMate-141, including patients not selected by a positive PD-L1 threshold. Previous exposure to a PD-1 inhibitor changes the question. Switching between pembrolizumab and nivolumab after clear immune resistance is not an established routine strategy.

After progression, possibilities include cetuximab with a taxane or another chemotherapy regimen, single-agent treatment, a clinical trial or symptom-focused care. Previous response and toxicity, the treatment-free interval and current fitness are important. There is no single sequence that fits everyone, and continuing an ineffective treatment can worsen symptoms and consume time.

Lower-cost approaches studied in India

Metronomic treatment uses a planned low-dose schedule. A Tata Memorial randomized study published in JCO in 2023 compared triple metronomic therapy—methotrexate, erlotinib and celecoxib—with the same regimen plus low-dose nivolumab. Adding nivolumab improved survival. This trial did not compare the combination with standard-dose pembrolizumab-based therapy.

A separate phase III trial presented as ASCO 2026 abstract LBA6007 compared triple oral metronomic therapy plus ultra-low-dose nivolumab against paclitaxel-carboplatin in platinum-sensitive recurrent or metastatic disease and reported improved survival. This is a different population and comparator from the earlier trial. The conference report should not be described as proof of equivalence to licensed full-dose immune regimens.

These approaches may be relevant when standard options are unaffordable or inaccessible, but require an oncologist experienced with the protocol and its safety monitoring. Oral drugs can cause serious toxicity and interactions. This guide deliberately provides no self-administration instructions. Approval, current guideline positioning, full-publication maturity and suitability should be verified locally.

Discussing what matters now

Ask what improvement is realistically expected, how soon it will be checked and what would make the team stop or change treatment. Discuss pain, eating, speaking, time at home, finances and travel. Early palliative-care involvement can support these goals while active treatment continues. Family discussions and advance-care planning help protect the patient’s wishes without taking away hope.

References and evidence review

Evidence/editorial check: 25 October 2026. AI-assisted preparation is distinct from individual physician review. See the linked review policy for source-access limits and review status. Regulatory indications, reimbursement and availability vary by country. Trial results alone do not establish approval everywhere; your treating team should confirm the applicable current guidance.